FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Scott Randal W.					2. Issuer Name and Ticker or Trading Symbol BridgeBio Pharma, Inc. [BBIO]								5. Relationship of Reportii (Check all applicable) Director			ng Person(s) to Issuer	
(Last)	Last) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 06/03/2024									Officer (give title below)		Othe belov	r (specify v)
C/O BRIDGEBIO PHARMA, INC. 3160 PORTER DR., SUITE 250					4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person				
(Street)	Street) PALO ALTO CA 94304													Form Perso		re than One Ro	eporting
,					Rule 10b5-1(c) Transaction Indication												
(City)	y) (State) (Zip)			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tabl	le I -	Non-Deriva	tive	Securi	ities A	cquir	ed, D	isposed o	of, or	Benefi	cially	Own	ed		
Date			2. Transaction Date (Month/Day/Ye	ar) E	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			i 5)	Securi Benefi Owned	cially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock				06/03/2024	4			S ⁽¹⁾		800	D	\$28.68	\$28.6844 ⁽²⁾		5,700		By Thinking Bench Capital LLC
Common Stock				06/03/2024	24			S ⁽¹⁾		200	D	\$29.475 ⁽³⁾		5	5,500	I	By Thinking Bench Capital LLC
Common Stock 06				06/04/2024	.4			S ⁽¹⁾		1,500	D	\$31.3		4,000		I	By Thinking Bench Capital LLC
Common	Stock													5	5,000	D	
		Т	able	II - Derivati	ve S	Securiti calls. w	es Ac	quired	d, Dis	posed of converti	, or B ble se	enefici ecuritie	ally (Owne	d		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Exe	3A. Deemed Execution Date, if any (Month/Day/Year)		saction e (Instr.	5. Numb of Derivativ Securitie Acquired (A) or Dispose of (D) (Instr. 3, and 5)	6. Date Ex Expiration (Month/Da		ercisable and Date	7. Tir Amo Secu Unde Deri	tle and ount of urities erlying vative urity (Instr	8. P Der Sec (Ins	gradie of vative urity r. 5) 9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership t (Instr. 4)	
					Code	e V	(A) (D	Dat Exe	e ercisable	Expiration e Date	n Title	Amoun or Numbe of Shares	r				

- 1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023.
- 2. Represents the weighted average sale price of the shares sold ranging from \$28.31 to \$29.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote
- 3. Represents the weighted average sale price of the shares sold ranging from \$29.44 to \$29.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

/s/ Brian C. Stephenson, Attorney-in-Fact

06/05/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.